The University of Cincinnati's Yasmin Aziz, MD, and Joseph Broderick, MD, coauthored an editorial published on Nov. 7 in the ...

We list the best online form builders, to make building forms simple and easy in order to collect customer feedback and marketing data. If you are looking for a simple, fast, and easy way to ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali ... the most common form of the disease.

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

One of the men argued in court that he did not know what “consent” meant. Another said he thought Mr. Pelicot, as her husband, could consent on her behalf. One man told the court he has learne ...

To continue this tradition, SABC 1’s Skeem Saam has aired a controversial episode that touches on how quickly and easily the lines of consent can be blurred. This storyline follows the characters of ...

New Developer Platform delivers more flexibility and control to unlock new workflows, applications, and material options. New bulk material pricing brings prices as low as $35 per liter for SLA ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

📱🚀 🧩 Cross Device & High Performance Normal Form/Dynamic(JSON Schema) Form/Form Builder -- Support React/React Native/Vue 2/Vue 3 ...